FDA approves Lilly’s new migraine attack drug, rival from Allergan could followThe FDA has approved Eli Lilly’s new migraine drug lasmiditan, offering patients a new option to relieve symptoms Share XFDA approves Lilly’s new migraine attack drug, rival from Allergan could followhttps://pharmaphorum.com/news/fda-approves-lillys-new-migraine-attack-drug-rival-from-allergan-could-follow/
After Alzheimer’s trial woes, Biogen’s R&D chief quits to head up biotech VCMichael Ehlers is to quit as head of Biogen’s troubled R&D outfit, taking a role as chief executive Share XAfter Alzheimer’s trial woes, Biogen’s R&D chief quits to head up biotech VChttps://pharmaphorum.com/news/after-alzheimers-trial-woes-biogens-rd-chief-quits-to-head-up-biotech-vc/
GW Pharma’s cannabis-derived epilepsy drug approved in EUGW Pharmaceuticals’ cannabis-derived drug Epidyolex has been approved in Europe for two kinds of rare childhood epilepsy. The Share XGW Pharma’s cannabis-derived epilepsy drug approved in EUhttps://pharmaphorum.com/news/gw-pharmas-cannabis-derived-epilepsy-drug-approved-in-eu/
bluebird presents long-term data from CALD gene therapybluebird bio has produced updated data from its gene therapy for the rare genetic neurological disease cerebral adrenoleukodystrophy Share Xbluebird presents long-term data from CALD gene therapyhttps://pharmaphorum.com/news/bluebird-presents-long-term-data-from-cald-gene-therapy/
Lundbeck to acquire Alder, and migraine drug, for $1.95bnLundbeck is to acquire Alder BioPharmaceuticals and its late-stage migraine drug eptinezumab in a deal worth up to Share XLundbeck to acquire Alder, and migraine drug, for $1.95bnhttps://pharmaphorum.com/news/lundbeck-to-acquire-alder-and-migraine-drug-for-1-95bn/
Citing phase 2 figures, Axon looks for big pharma investment for Alzheimer’s vaccineAfter trial failure upon trial failure in Alzheimer’s disease will big pharma be prepared to fund a trial Share XCiting phase 2 figures, Axon looks for big pharma investment for Alzheimer’s vaccinehttps://pharmaphorum.com/r-d/uk-biotech-axon-looks-for-big-pharma-investment-for-alzheimers-vaccine/
FDA approves Kyowa Kirin’s new Parkinson’s drug NourianzThe FDA has approved a new drug for Parkinson’s disease, giving the nod to Kyowa Kirin’s Nourianz (istadefylline) Share XFDA approves Kyowa Kirin’s new Parkinson’s drug Nourianzhttps://pharmaphorum.com/news/fda-approves-kyowa-kirins-new-parkinsons-drug-nourianz/
Alzheimer’s blood test could boost research after successive trial failuresA blood test could be used to diagnose Alzheimer’s before symptoms arise, providing an alternative to expensive brain Share XAlzheimer’s blood test could boost research after successive trial failureshttps://pharmaphorum.com/news/alzheimers-blood-test-could-boost-research-after-successive-trial-failures/
FDA fast-tracks NeuroVive’s traumatic brain injury drugThe FDA has fast-tracked a drug to treat severe traumatic brain injury from Swedish pharma NeuroVive, hastening its Share XFDA fast-tracks NeuroVive’s traumatic brain injury drughttps://pharmaphorum.com/news/fda-fast-tracks-neurovives-traumatic-brain-injury-drug/
